Shielding the ovaries: a drug may help young breast cancer patients preserve fertility during chemo
NCT ID NCT07127315
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This trial tests whether giving goserelin, a hormone-blocking drug, alongside chemotherapy can help preserve ovarian function and fertility in premenopausal women with breast cancer. Participants receive either chemotherapy plus goserelin or chemotherapy alone. Researchers will measure hormone levels and long-term outcomes like disease-free and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Goserelin, a gonadotropin-releasing hormone agonist, given alongside chemotherapy
- What this could lead to
- If effective, this approach could help preserve fertility and ovarian function in young breast cancer patients undergoing chemotherapy.
- What could go wrong
- The trial is relatively small and early, and results may not apply to all patients. Goserelin has side effects and may not fully protect ovarian function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
100 people
The number who actually took part.
- Started
-
Jun 2022
- Finished
-
Jul 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Premenopausal female patients 18-45 years. * Female patients with pathologically confirmed breast cancer and receiving a chemotherapy regimen, either adjuvant or neoadjuvant, containing a gonadotoxic agent. * Female patients with performance status (PS) ≤ 2. Exclusion Criteria: * All female Patients with metastatic cancer. * Patients underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy, or patients received radiotherapy on the pelvis. * Patient with end-organ failure. * Patients with performance status \>2. * Male with breast cancer. * Post-menopausal females.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Helwan University
Helwan, Helwan, 11795, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster radiation course match the standard one after breast reconstruction?
- Can High-Risk breast cancer patients skip an extra radiation boost?
- Radioactive probe lights up CD73 on breast tumors in PET scans
- Can time with horses help cancer patients feel better?
- Can an oral drug replace injections for advanced breast cancer?
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?